Single-cell transcriptomic inference of lactylation-related programs identifies PRDX1 as a candidate metabolic regulator in hepatocellular carcinoma
This study integrates single-cell and bulk transcriptomic data to define a lactylation-related program in hepatocellular carcinoma, identifying PRDX1 as a key metabolic regulator that links lactate metabolism to malignant phenotypes and poor patient survival.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Liver cancer, known medically as hepatocellular carcinoma, is a disease defined by chaos. Inside a tumor, millions of cells are not just growing uncontrollably; they are also rewiring their internal chemistry to survive. One of the most famous changes is that these cancer cells burn sugar for energy in a way that produces a lot of lactic acid, even when oxygen is available. For decades, scientists viewed this lactic acid merely as a waste product, a sign that the cell was struggling. However, recent discoveries have revealed that lactic acid is also a powerful signal. It can attach itself to proteins inside the cell, acting like a switch that turns genes on or off. This process, called lactylation, helps cancer cells grow, spread, and resist treatment. Understanding exactly which cells are using this signal and how they are using it could reveal new ways to stop the disease.
A team of researchers set out to map this hidden landscape within liver cancer. They did not look at the tumor as a single, uniform mass. Instead, they treated it like a crowded city, examining the individual citizens—different types of cells—living within it. By analyzing genetic data from 24 separate samples of liver tissue, including both healthy livers and tumors, they used a technique that reads the genetic instructions of single cells one by one. This allowed them to see which cells were active in the lactic acid signaling program and which were not. They found that this activity was not spread evenly. The cells with the highest levels of this lactic acid signaling were the cancer cells themselves and a specific type of immune cell called a myeloid dendritic cell. In contrast, other immune cells, such as B cells and plasma cells, showed very little of this activity.
The researchers then focused on the cancer cells that were most active in this lactic acid program. They discovered that these specific cells were not just growing; they were behaving like immature, stem-like cells that are harder to kill and more likely to spread. These high-activity cells also sent out different chemical signals to their neighbors compared to less active cancer cells, suggesting they were reshaping the environment around them to their advantage. To find the specific genes driving this behavior, the team used a combination of statistical methods to sift through thousands of genetic candidates. They narrowed the list down to four key genes that appeared most consistently in the most aggressive cancer cells. Among these four, one gene stood out as a particularly strong candidate for controlling the cancer's behavior: a gene called PRDX1.
To test if this gene was truly important, the researchers moved from computer analysis to the laboratory. They took liver cancer cells grown in a dish and used a precise tool to turn down the activity of the PRDX1 gene. The results were immediate and clear. When the PRDX1 gene was silenced, the cancer cells stopped growing as fast, struggled to form new colonies, and lost their ability to move and invade surrounding tissue. Perhaps most importantly, these cells produced significantly less lactic acid. This experiment showed that PRDX1 is not just a bystander in the disease; it appears to be a regulator that helps the cancer cells maintain their aggressive nature and their unique way of making energy.
The study suggests that the PRDX1 gene acts as a link between the cancer cell's metabolism and its ability to thrive. While the researchers have not yet proven exactly how PRDX1 controls the lactic acid switches on the proteins, their work points to it as a critical piece of the puzzle. The findings indicate that in liver cancer, the ability to produce lactic acid and the ability to grow aggressively are controlled by the same genetic machinery. By identifying PRDX1, the study offers a new target for future research. If scientists can find a way to block this gene or the pathway it controls, they might be able to stop the cancer cells from using lactic acid to fuel their growth and spread. This approach would not just treat the symptoms of the disease but could potentially cut off the energy source that allows the tumor to survive and resist therapy.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.